Beech Tree raises series B to complete Phase II antiviral trials
This article was originally published in Scrip
Executive Summary
Beech Tree Labs has closed an over-subscribed series B round where it raised $7 million from undisclosed investors. The funds will be used to finish two Phase II trials currently in progress with Beech's lead drug candidate, BTL-TML, for influenza and recurrent oral herpes.